Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matteo Ferro

Showing results (261-270 of 420) with videos related to

Pageof 42
Sort By:
World Journal of Urology|March 29, 2022
Association between previous negative biopsies and lower rates of progression during active surveillance for prostate cancerMattia Luca Piccinelli, Stefano Luzzago, Giulia Marvaso, et al.
World Journal of Urology|December 7, 2018
Incidence of fatigue and low-dose corticosteroid use in prostate cancer patients receiving systemic treatment: a meta-analysis of randomized controlled trialsMatteo Ferro, Giuseppe Di Lorenzo, Ottavio de Cobelli, et al.
Prostate Cancer and Prostatic Diseases|December 15, 2019
Correction: Confirmatory multiparametric magnetic resonance imaging at recruitment confers prolonged stay in active surveillance and decreases the rate of upgrading at follow-upStefano Luzzago, Michele Catellani, Ettore Di Trapani, et al.
Medicine|June 15, 2017
PSA declines and survival in patients with metastatic castration-resistant prostate cancer treated with enzalutamide: A retrospective case-report studyDavide Bosso, Martina Pagliuca, Guru Sonpavde, et al.
Diagnostics (Basel, Switzerland)|September 28, 2023
Predicting Peri-Operative Outcomes in Patients Treated with Percutaneous Thermal Ablation for Small Renal Masses: The SuNS Nephrometry ScoreGennaro Musi, Stefano Luzzago, Giovanni Mauri, et al.
Prostate Cancer and Prostatic Diseases|September 29, 2020
MRI-targeted or systematic random biopsies for prostate cancer diagnosis in biopsy naïve patients: follow-up of a PRECISION trial-like retrospective cohortStefano Luzzago, Ottavio de Cobelli, Francesco A Mistretta, et al.
Cancers|March 28, 2024
Upper Tract Urothelial Cancer: Guideline of GuidelinesSavio Domenico Pandolfo, Simone Cilio, Achille Aveta, et al.
BJU International|March 10, 2020
A novel nomogram to identify candidates for active surveillance amongst patients with International Society of Urological Pathology (ISUP) Grade Group (GG) 1 or ISUP GG2 prostate cancer, according to multiparametric magnetic resonance imaging findingsStefano Luzzago, Ottavio de Cobelli, Gabriele Cozzi, et al.
Journal of Clinical Medicine|April 26, 2025
Which Surrogate Marker of Insulin Resistance Among Those Proposed in the Literature Better Predicts the Presence of Non-Metastatic Bladder Cancer?Giovanni Tarantino, Ciro Imbimbo, Matteo Ferro, et al.
Critical Reviews in Oncology/Hematology|July 25, 2025
Emerging biomarkers in bladder cancer: Translating molecular advances into precision oncologyMatteo Ferro, Felice Crocetto, Letizia Maria Ippolita Jannello, et al.
Pageof 42

Showing results (261-270 of 420) with videos related to

Sort By:
Pageof 42
World Journal of Urology|March 29, 2022
Association between previous negative biopsies and lower rates of progression during active surveillance for prostate cancerMattia Luca Piccinelli, Stefano Luzzago, Giulia Marvaso, et al.
World Journal of Urology|December 7, 2018
Incidence of fatigue and low-dose corticosteroid use in prostate cancer patients receiving systemic treatment: a meta-analysis of randomized controlled trialsMatteo Ferro, Giuseppe Di Lorenzo, Ottavio de Cobelli, et al.
Prostate Cancer and Prostatic Diseases|December 15, 2019
Correction: Confirmatory multiparametric magnetic resonance imaging at recruitment confers prolonged stay in active surveillance and decreases the rate of upgrading at follow-upStefano Luzzago, Michele Catellani, Ettore Di Trapani, et al.
Medicine|June 15, 2017
PSA declines and survival in patients with metastatic castration-resistant prostate cancer treated with enzalutamide: A retrospective case-report studyDavide Bosso, Martina Pagliuca, Guru Sonpavde, et al.
Diagnostics (Basel, Switzerland)|September 28, 2023
Predicting Peri-Operative Outcomes in Patients Treated with Percutaneous Thermal Ablation for Small Renal Masses: The SuNS Nephrometry ScoreGennaro Musi, Stefano Luzzago, Giovanni Mauri, et al.
Prostate Cancer and Prostatic Diseases|September 29, 2020
MRI-targeted or systematic random biopsies for prostate cancer diagnosis in biopsy naïve patients: follow-up of a PRECISION trial-like retrospective cohortStefano Luzzago, Ottavio de Cobelli, Francesco A Mistretta, et al.
Cancers|March 28, 2024
Upper Tract Urothelial Cancer: Guideline of GuidelinesSavio Domenico Pandolfo, Simone Cilio, Achille Aveta, et al.
BJU International|March 10, 2020
A novel nomogram to identify candidates for active surveillance amongst patients with International Society of Urological Pathology (ISUP) Grade Group (GG) 1 or ISUP GG2 prostate cancer, according to multiparametric magnetic resonance imaging findingsStefano Luzzago, Ottavio de Cobelli, Gabriele Cozzi, et al.
Journal of Clinical Medicine|April 26, 2025
Which Surrogate Marker of Insulin Resistance Among Those Proposed in the Literature Better Predicts the Presence of Non-Metastatic Bladder Cancer?Giovanni Tarantino, Ciro Imbimbo, Matteo Ferro, et al.
Critical Reviews in Oncology/Hematology|July 25, 2025
Emerging biomarkers in bladder cancer: Translating molecular advances into precision oncologyMatteo Ferro, Felice Crocetto, Letizia Maria Ippolita Jannello, et al.
Pageof 42